ToolGen Incorporated

A199800

KR7199800004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
64,600 ^KRW	+6.95%		+0.62%	-7.98%

2023	ToolGen Incorporated announced that it has received KRW 33 billion in funding	CI
2023	ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	CI

ToolGen Incorporated announced that it has received KRW 10.0223744 billion in funding

October 13, 2016

On October 14, 2016, ToolGen Incorporated (XKON:A199800) closed the transaction.

Latest news about ToolGen Incorporated

ToolGen Incorporated announced that it has received KRW 33 billion in funding	11-01	CI
ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	30/10/23	CI
Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques	18/04/23	CI
ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index	19/09/22	CI
MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc	15/06/22	CI
ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.	06/12/21	CI
ToolGen Incorporated has filed an IPO.	14/09/21	CI
ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.	20/12/20	CI
ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc.	10/12/20	CI
Genexine, Inc. cancelled the acquisition of ToolGen Incorporated.	19/08/19	CI
Genexine, Inc. agreed to acquire ToolGen Incorporated for approximately KRW 350 billion.	18/06/19	CI
ToolGen, Inc., Demonstrates CRISPR/Cas9 Gene Editing Improves Anti-Tumor Activity of Human Car-T Cells	17/05/18	CI
Monsanto Company and ToolGen, Inc. Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers	18/08/17	CI
ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing	22/02/17	CI
ToolGen Incorporated announced that it has received KRW 10.0223744 billion in funding	13/10/16	CI
ToolGen Incorporated announced that it expects to receive KRW 10.0223744 billion in funding	12/10/16	CI
Jong-Moon Kim acquired an additional unknown stake in ToolGen Incorporated from Seong-Hak Choi for KRW 2.7 billion.	11/02/16	CI
ToolGen, Inc. Signs License Agreement with Thermo Fisher Scientific	11/03/15	CI
ToolGen Incorporated announced that it has received KRW 2 billion in funding.	10/10/14	CI
ToolGen Incorporated announced that it expects to receive KRW 2 billion in funding.	07/10/14	CI

ToolGen, Inc. is principally engaged in the development of engineered nucleases. The Companyâs main products portfolio consists of ribose nucleic acid (RNA)-guided endonucleases (RGEN) as well as deoxyribonucleic acid (DNA)-directed RGEN (dRGEN), which are applied as tools for editing genetic information in microbial, plant, animal and human cells. In addition, it is involved in the provision of genome engineering services.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TOOLGEN INCORPORATED	-7.98%	375M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B